This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mosquera, J.
Right arrow Articles by Denning, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mosquera, J.
Right arrow Articles by Denning, D. W.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2002, p. 556-557, Vol. 46, No. 2
0066-4804/01/$04.00+0     DOI: 10.1128/AAC.46.2.556-557.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Azole Cross-Resistance in Aspergillus fumigatus

J. Mosquera1 and D. W. Denning1,2*

School of Medicine, University of Manchester, Manchester M13 9PT,1 Department of Medicine, Wythenshawe Hospital, Manchester M29 9LT, United Kingdom2

Received 4 June 2001/ Returned for modification 7 August 2001/ Accepted 22 October 2001


arrow
ABSTRACT
 
We susceptibility tested 17 clinical isolates of Aspergillus fumigatus, for most of which MICs of itraconazole were elevated (MIC at which 50% of the isolates tested are inhibited, 16 µg/ml), against itraconazole, posaconazole, ravuconazole, and voriconazole. Posaconazole was the most active against itraconazole-susceptible isolates. A complex pattern of cross-resistance and hypersusceptibility was seen with voriconazole and ravuconazole, suggesting marked differences in activity and mechanisms of resistance.


arrow
INTRODUCTION
 
Invasive aspergillosis is now the most common invasive mould infection worldwide and is increasing rapidly in frequency (4). Amphotericin B and itraconazole (ITC) were the only two agents licensed for the treatment of Aspergillus infections, until the recent licensure of caspofungin for salvage usage. Response rates are poor (typically 35 to 55%). Resistance has been described and may contribute to failure (9). Several promising new agents are undergoing clinical trials, including three new azoles with good activity against Aspergillus in vitro and in animal models: posaconazole (SCH 56592; PCZ), voriconazole (UK 109496; VRC), and ravuconazole (BMS-207147; RVZ). In vivo resistance to ITC (2, 6) and elevated VRC MICs (12) have already been described for Aspergillus fumigatus clinical isolates, as well as elevated ITC MICs for Aspergillus nidulans (3). Our own work over several years has shown a maximum ITC resistance rate of 4.2% in Aspergillus spp. (MIC > 4 µg/ml), using an inoculum that may overestimate resistance. Of 900 isolates of A. fumigatus tested in the recent literature against ITC, 2.1% are reported to be resistant (9). No study has investigated azole cross-resistance in more than a handful of clinical Aspergillus isolates.

We have tested 17 different clinical isolates of A. fumigatus, for which MICs range from 0.13 to 16 µg/ml (ITC, VRC, RVZ, and PCZ). Eleven of those isolates we have defined as resistant to ITC in vitro (MIC > 4 µg/ml). Breakpoints have yet to be validated in vivo. We have employed a final inoculum of 5 x 104 CFU/ml, 10-fold lower than in previous work with A. fumigatus, in which we used 5 x 105 CFU/ml, for three reasons. First, a wider range of MICs is obtained as the lower inoculum lowers MICs and as there is an upper limit of ITC solubility (8 µg/ml). Second, unpublished and published work (10) from our lab shows that, in some but not all Aspergillus flavus isolates, a final inoculum of 5 x 105 CFU/ml disproportionately increases MICs (due to trailing), falsely suggesting resistance. Third, a recent NCCLS reproducibility study showed that, with the final inoculum range recommended by the NCCLS, between 0.4 and 5 x 104 CFU/ml, good reproducibility is obtained and resistance is identified (7). Fourth, the lowest NCCLS inoculum may fail to identify elevated MICs for some isolates because the MIC distribution is too narrow.

All strains were obtained from different patients, with the exception of FA/5211, FA/6919, and FA/7075 from one patient and 1112 and 1237 from another, in both of whom resistant strains appeared on therapy with ITC (1). ITC (Janssen Research Foundation, Beerse, Belgium), VRC (Pfizer, Sandwich, United Kingdom), PCZ (Schering-Plough Research Institute, Bloomfield, N.J.), and RVZ (Bristol-Myers Squibb Company, Princeton, N.J.) were obtained as standard powders from their respective manufacturers. They were dissolved in dimethyl sulfoxide (Sigma, Poole, United Kingdom). In vitro susceptibility testing was performed with a broth microdilution-based method, validated in vivo in our laboratory, that was capable of detecting ITC resistance in A. fumigatus (5). RPMI 1640 plus 2% glucose (pH 7.0) as testing medium, a final inoculum of 5 x 104 CFU/ml, a 48-h incubation period at 37°C, and a visual no-growth endpoint were used. Dilution ranges were 8 to 0.008 µg/ml for ITC, 4 to 0.004 µg/ml for PCZ, 64 to 0.06 µg/ml for VRC, and 32 to 0.03 µg/ml for RVZ. Reproducibility studies showed that, for all four drugs, 100% (eight out of eight) of isolates retested gave a result within one twofold dilution.

Median MICs (in micrograms per milliliter) were ITC, 16; PCZ, 1; VRC, 0.5; and RVZ, 1. Elevated ITC MICs were uniformly associated with elevations in PCZ MICs of 4- to 256-fold, as the PCZ MICs for isolates fully susceptible to ITC generally are 0.03 µg/ml (Fig. 1).The impact of this MIC shift has been documented in vivo (11). However, the clinical implications of elevated PCZ MICs are not known, since achievable serum drug concentrations far exceed this concentration. High doses of PCZ could overcome elevated MICs, as shown in a murine model for the ITC-resistant isolate AF90 (PCZ MIC, 1 µg/ml) (11). A recent study conducted on azole cross-resistance, employing a significant number of laboratory-selected isolates for which ITC MICs were elevated, showed only a slight (two- to threefold) increase in PCZ MICs (8).



View larger version (68K):
[in this window]
[in a new window]
  		FIG. 1. MICs for the A. fumigatus isolates of ITC (ITZ), PCZ, VRC (VCZ), and RVZ are given in micrograms per milliliter. A, AF41 (fully susceptible); B, F/6631; C, F/5211; D, IHEM 17905; E, SO/3626; F, F/7763; G, Br181; H, SO/3827; I, SO/3829; J, Br130; K, Br128; L, AF90; M, AF72; N, AF1422; O, IHEM 17907; P, F/6919; and Q, F/7075.

Elevated ITC MICs were not usually associated with elevated MICs of VRC or RVZ. For only 3 out of the 11 ITC in vitro resistant isolates did RVZ MICs increase by more than twofold (MIC, 4 to 8 µg/ml), compared to the result for the most ITC-susceptible isolate (MIC, 0.5 µg/ml). VRC MICs varied between 0.06 and 2 µg/ml, and RVZ MICs ranged from 0.03 to 8 µg/ml. The susceptibility pattern of the isolates against VRC and RVZ was very similar, suggesting similar modes of action and mechanisms of resistance. Interestingly, the lowest VRC and RVZ MICs were seen for highly ITC-resistant isolates. For 5 of 11 and 7 of 11 of the ITC-resistant isolates, RVZ and VRC MICs (2- to 16-fold), respectively, decreased, compared to the MICs for the most ITC-susceptible isolate. For the isolate for which the RCZ MIC was highest, the VRC MIC was low, but the ITC and PCZ MICs were both elevated.

These data indicate substantial heterogeneity in susceptibility among isolates of A. fumigatus and suggest the existence of different mechanisms of resistance against antifungal azoles. As might be expected from structural considerations, the susceptibility patterns of ITC and PCZ are similar (although PCZ is consistently more active than ITC), as are those of VRC and RVZ. However, individual variations of MICs are not entirely predictable and testing of each isolate to each drug is likely to be valuable. Optimizing therapy for those few patients in whom an isolate is grown, by selecting the most active azole drug, is now feasible. Reproducibility of results and definition of breakpoints will be important for clinical acceptance. Clearly, subtle variations in the specific mode of action of each azole against A. fumigatus isolate are revealed by this work, but they are barely understood. New studies are warranted in order to analyze the mechanisms involved in these complex azole susceptibility patterns.

This work has been supported by the European Commission Training and Mobility of Researchers grant FMRX-CT970145 Eurofung and the Fungal Research Trust.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Education and Research Centre, Wythenshawe Hospital, Southmoor Rd., Manchester M29 9LT, United Kingdom. Phone: 44 161 291 5054. Fax: 44 161 291 5020. E-mail: ddenning{at}man.ac.uk.. Back


arrow
REFERENCES
 
    1
  1. Dannaoui, E., E. Borel, M. Monier, M. Piens, S. Picot, and F. Persat. 2001. Acquired itraconazole resistance in Aspergillus fumigatus. J. Antimicrob. Chemother. 47:333-340.[Abstract/Free Full Text]
    2. 2
  2. Dannaoui, E., E. Borel, F. Persat, M. F. Monier, and M. A. Piens. 1999. In-vivo itraconazole resistance of Aspergillus fumigatus in systemic murine aspergillosis. EBGA Network. European research group on Biotypes and Genotypes of Aspergillus fumigatus. J. Med. Microbiol. 48:1087-1093.[Abstract/Free Full Text]
    3. 3
  3. Dannaoui, E., F. Persat, M. F. Monier, E. Borel, M. A. Piens, and S. Picot. 1999. In-vitro susceptibility of Aspergillus spp. isolates to amphotericin B and itraconazole. J. Antimicrob. Chemother. 44:553-555.[Abstract/Free Full Text]
    4. 4
  4. Denning, D. W. 1998. Invasive aspergillosis. Clin. Infect. Dis. 26:781-805.
    5. 5
  5. Denning, D. W., S. A. Radford, K. L. Oakley, L. Hall, E. M. Johnson, and D. W. Warnock. 1997. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J. Antimicrob. Chemother. 40:401-414.[Abstract/Free Full Text]
    6. 6
  6. Denning, D. W., K. Venkateswarlu, K. L. Oakley, M. J. Anderson, N. J. Manning, D. A. Stevens, D. W. Warnock, and S. L. Kelly. 1997. Itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 41:1364-1368.[Abstract]
    7. 7
  7. Espinel-Ingroff, A., M. Bartlett, V. Chaturvedi, M. Ghannoum, K. C. Hazen, M. A. Pfaller, M. Rinaldi, and T. J. Walsh. 2001. Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. Antimicrob. Agents Chemother. 45:1828-1835.[Abstract/Free Full Text]
    8. 8
  8. Manavathu, E. K., J. L. Cutright, D. Loebenberg, and P. H. Chandrasekar. 2000. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J. Antimicrob. Chemother. 46:229-234.[Abstract/Free Full Text]
    9. 9
  9. Moore, C. B., N. Sayers, J. Mosquera, J. Slaven, and D. W. Denning. 2000. Antifungal drug resistance in Aspergillus. J. Infect. 41:203-220.[CrossRef][Medline]
    10. 10
  10. Mosquera, J., P. A. Warn, J. Morrissey, C. B. Moore, C. Gil-Lamaignere, and D. W. Denning. 2001. Susceptibility testing of Aspergillus flavus: inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B in vitro and outcome in vivo. Antimicrob. Agents Chemother. 45:1456-1462.[Abstract/Free Full Text]
    11. 11
  11. Oakley, K. L., G. Morrissey, and D. W. Denning. 1997. Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob. Agents Chemother. 41:1504-1507.[Abstract]
    12. 12
  12. Verweij, P. E., M. Mensink, A. J. Rijs, J. P. Donnelly, J. F. Meis, and D. W. Denning. 1998. In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. J. Antimicrob. Chemother. 42:389-392.[Abstract/Free Full Text]

Antimicrobial Agents and Chemotherapy, February 2002, p. 556-557, Vol. 46, No. 2
0066-4804/01/$04.00+0     DOI: 10.1128/AAC.46.2.556-557.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Pfaller, M. A., Diekema, D. J., Ghannoum, M. A., Rex, J. H., Alexander, B. D., Andes, D., Brown, S. D., Chaturvedi, V., Espinel-Ingroff, A., Fowler, C. L., Johnson, E. M., Knapp, C. C., Motyl, M. R., Ostrosky-Zeichner, L., Sheehan, D. J., Walsh, T. J., for the Clinical and Laboratory Standards Institut, (2009). Wild-Type MIC Distribution and Epidemiological Cutoff Values for Aspergillus fumigatus and Three Triazoles as Determined by the Clinical and Laboratory Standards Institute Broth Microdilution Methods. J. Clin. Microbiol. 47: 3142-3146 [Abstract] [Full Text]  
  • Baddley, J. W., Marr, K. A., Andes, D. R., Walsh, T. J., Kauffman, C. A., Kontoyiannis, D. P., Ito, J. I., Balajee, S. A., Pappas, P. G., Moser, S. A. (2009). Patterns of Susceptibility of Aspergillus Isolates Recovered from Patients Enrolled in the Transplant-Associated Infection Surveillance Network. J. Clin. Microbiol. 47: 3271-3275 [Abstract] [Full Text]  
  • Tiralongo, J., Wohlschlager, T., Tiralongo, E., Kiefel, M. J. (2009). Inhibition of Aspergillus fumigatus conidia binding to extracellular matrix proteins by sialic acids: a pH effect?. Microbiology 155: 3100-3109 [Abstract] [Full Text]  
  • Morris, M. I. (2009). Posaconazole: A new oral antifungal agent with an expanded spectrum of activity. Am J Health Syst Pharm 66: 225-236 [Abstract] [Full Text]  
  • Lass-Florl, C., Mayr, A., Perkhofer, S., Hinterberger, G., Hausdorfer, J., Speth, C., Fille, M. (2008). Activities of Antifungal Agents against Yeasts and Filamentous Fungi: Assessment according to the Methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob. Agents Chemother. 52: 3637-3641 [Abstract] [Full Text]  
  • Lamaris, G. A., Ben-Ami, R., Lewis, R. E., Kontoyiannis, D. P. (2008). Does pre-exposure of Aspergillus fumigatus to voriconazole or posaconazole in vitro affect its virulence and the in vivo activity of subsequent posaconazole or voriconazole, respectively? A study in a fly model of aspergillosis. J Antimicrob Chemother 62: 539-542 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Boyken, L., Rice, C., Tendolkar, S., Hollis, R. J., Diekema, D. J. (2008). In Vitro Survey of Triazole Cross-Resistance among More than 700 Clinical Isolates of Aspergillus Species. J. Clin. Microbiol. 46: 2568-2572 [Abstract] [Full Text]  
  • Alcazar-Fuoli, L., Mellado, E., Alastruey-Izquierdo, A., Cuenca-Estrella, M., Rodriguez-Tudela, J. L. (2008). Aspergillus Section Fumigati: Antifungal Susceptibility Patterns and Sequence-Based Identification. Antimicrob. Agents Chemother. 52: 1244-1251 [Abstract] [Full Text]  
  • Garcia-Effron, G., Dilger, A., Alcazar-Fuoli, L., Park, S., Mellado, E., Perlin, D. S. (2008). Rapid Detection of Triazole Antifungal Resistance in Aspergillus fumigatus. J. Clin. Microbiol. 46: 1200-1206 [Abstract] [Full Text]  
  • Mellado, E., Garcia-Effron, G., Alcazar-Fuoli, L., Melchers, W. J. G., Verweij, P. E., Cuenca-Estrella, M., Rodriguez-Tudela, J. L. (2007). A New Aspergillus fumigatus Resistance Mechanism Conferring In Vitro Cross-Resistance to Azole Antifungals Involves a Combination of cyp51A Alterations. Antimicrob. Agents Chemother. 51: 1897-1904 [Abstract] [Full Text]  
  • Dannaoui, E., Garcia-Hermoso, D., Naccache, J. M., Meneau, I., Sanglard, D., Bouges-Michel, C., Valeyre, D., Lortholary, O. (2006). Use of voriconazole in a patient with aspergilloma caused by an itraconazole-resistant strain of Aspergillus fumigatus.. J Med Microbiol 55: 1457-1459 [Abstract] [Full Text]  
  • McLellan, G. J., Aquino, S. M., Mason, D. R., Kinyon, J. M., Myers, R. K. (2006). Use of Posaconazole in the Management of Invasive Orbital Aspergillosis in a Cat. Journal of the American Animal Hospital Association 42: 302-307 [Abstract] [Full Text]  
  • Alcazar-Fuoli, L., Mellado, E., Garcia-Effron, G., Buitrago, M. J., Lopez, J. F., Grimalt, J. O., Cuenca-Estrella, J. M., Rodriguez-Tudela, J. L. (2006). Aspergillus fumigatus C-5 Sterol Desaturases Erg3A and Erg3B: Role in Sterol Biosynthesis and Antifungal Drug Susceptibility. Antimicrob. Agents Chemother. 50: 453-460 [Abstract] [Full Text]  
  • Garcia-Effron, G., Mellado, E., Gomez-Lopez, A., Alcazar-Fuoli, L., Cuenca-Estrella, M., Rodriguez-Tudela, J. L. (2005). Differences in Interactions between Azole Drugs Related to Modifications in the 14-{alpha} Sterol Demethylase Gene (cyp51A) of Aspergillus fumigatus. Antimicrob. Agents Chemother. 49: 2119-2121 [Abstract] [Full Text]  
  • Cuenca-Estrella, M., Gomez-Lopez, A., Garcia-Effron, G., Alcazar-Fuoli, L., Mellado, E., Buitrago, M. J., Rodriguez-Tudela, J. L. (2005). Combined Activity In Vitro of Caspofungin, Amphotericin B, and Azole Agents against Itraconazole-Resistant Clinical Isolates of Aspergillus fumigatus. Antimicrob. Agents Chemother. 49: 1232-1235 [Abstract] [Full Text]  
  • Hsueh, P.-R., Lau, Y.-J., Chuang, Y.-C., Wan, J.-H., Huang, W.-K., Shyr, J.-M., Yan, J.-J., Yu, K.-W., Wu, J.-J., Ko, W.-C., Yang, Y.-C., Liu, Y.-C., Teng, L.-J., Liu, C.-Y., Luh, K.-T. (2005). Antifungal Susceptibilities of Clinical Isolates of Candida Species, Cryptococcus neoformans, and Aspergillus Species from Taiwan: Surveillance of Multicenter Antimicrobial Resistance in Taiwan Program Data from 2003. Antimicrob. Agents Chemother. 49: 512-517 [Abstract] [Full Text]  
  • Xiong, Q., Hassan, S. A., Wilson, W. K., Han, X. Y., May, G. S., Tarrand, J. J., Matsuda, S. P. T. (2005). Cholesterol Import by Aspergillus fumigatus and Its Influence on Antifungal Potency of Sterol Biosynthesis Inhibitors. Antimicrob. Agents Chemother. 49: 518-524 [Abstract] [Full Text]  
  • Linares, M. J., Charriel, G., Solis, F., Rodriguez, F., Ibarra, A., Casal, M. (2005). Susceptibility of Filamentous Fungi to Voriconazole Tested by Two Microdilution Methods. J. Clin. Microbiol. 43: 250-253 [Abstract] [Full Text]  
  • Araujo, R., Rodrigues, A. G., Pina-Vaz, C. (2004). A fast, practical and reproducible procedure for the standardization of the cell density of an Aspergillus suspension. J Med Microbiol 53: 783-786 [Abstract] [Full Text]  
  • Mellado, E., Garcia-Effron, G., Alcazar-Fuoli, L., Cuenca-Estrella, M., Rodriguez-Tudela, J. L. (2004). Substitutions at Methionine 220 in the 14{alpha}-Sterol Demethylase (Cyp51A) of Aspergillus fumigatus Are Responsible for Resistance In Vitro to Azole Antifungal Drugs. Antimicrob. Agents Chemother. 48: 2747-2750 [Abstract] [Full Text]  
  • Gomez-Lopez, A., Garcia-Effron, G., Mellado, E., Monzon, A., Rodriguez-Tudela, J. L., Cuenca-Estrella, M. (2003). In Vitro Activities of Three Licensed Antifungal Agents against Spanish Clinical Isolates of Aspergillus spp.. Antimicrob. Agents Chemother. 47: 3085-3088 [Abstract] [Full Text]  
  • Nascimento, A. M., Goldman, G. H., Park, S., Marras, S. A. E., Delmas, G., Oza, U., Lolans, K., Dudley, M. N., Mann, P. A., Perlin, D. S. (2003). Multiple Resistance Mechanisms among Aspergillus fumigatus Mutants with High-Level Resistance to Itraconazole. Antimicrob. Agents Chemother. 47: 1719-1726 [Abstract] [Full Text]  
  • Diaz-Guerra, T. M., Mellado, E., Cuenca-Estrella, M., Rodriguez-Tudela, J. L. (2003). A Point Mutation in the 14{alpha}-Sterol Demethylase Gene cyp51A Contributes to Itraconazole Resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 47: 1120-1124 [Abstract] [Full Text]  
  • Warris, A., Weemaes, C. M., Verweij, P. E. (2002). Multidrug Resistance in Aspergillus fumigatus. NEJM 347: 2173-2174 [Full Text]  
  • Mosquera, J., Sharp, A., Moore, C. B., Warn, P. A., Denning, D. W. (2002). In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp.. J Antimicrob Chemother 50: 189-194 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mosquera, J.
Right arrow Articles by Denning, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mosquera, J.
Right arrow Articles by Denning, D. W.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»